You are here
BIOSTRATAGIES LC
UEI: PE6MEQZRFW63
# of Employees: 1
HUBZone Owned: No
Socially and Economically Disadvantaged: Yes
Woman Owned: No
Award Charts
Award Listing
-
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
Amount: $1,500,000.00PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sa ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
Amount: $295,923.00Mucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, mus ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS
Amount: $390,497.00Krabbe disease (globoid cell leukodystrophy) is a rare inherited disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC) leading to destruction of the protective coating (m ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery
Amount: $250,000.00The current inability to effectively deliver corrective doses of lysosomal enzymes to key cells involved in muscular disease symptoms remains a significant hurdle for rare lysosomal disorders (LSD) su ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
Amount: $2,049,999.00The long-range goal of this research is to develop an enzyme replacement therapy (ERT) technology for genetic metabolic diseases that is effective in mitigating the problem of immune sensitization tha ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease
Amount: $293,232.00The current inability to effectively deliver corrective doses of lysosomal enzymes to key cells involved in cardiovascular and cerebrovascular disease remains a significant hurdle for rare lysosomal d ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme
Amount: $225,000.00BioStrategies LC is developing the plant galactose binding lectinRTBas an enzyme carrier capable of expanding delivery of enzyme replacement therapiesERTstohardto treatorgans and tissues such as boneT ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease
Amount: $2,438,483.00The goal of this SBIR proposal is to develop an effective enzyme replacement therapyERTfor patients suffering from GMGangliosidosis by applying a novel ERT enzyme lectin fusion delivery strategy devel ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Improving MPS I ERT Efficacy through Lectin Mediated Delivery
Amount: $1,237,037.00The long term goal of this project is to develop an improved ERT for MPS I patients with innovations that enhance ERT delivery and disease correction in hard to treat organs such as the brain while in ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
Amount: $2,384,044.00The long term goal of this project is to develop an improved ERT for MPS I patients with innovations that enhance ERT delivery and disease correction in hard to treat organs such as the brain while in ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health